<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-09-15</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39272698/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Prospective Comparison of Nine Different Handheld Ultrasound (HHUS) Devices by Ultrasound Experts with Regard to B-Scan Quality, Device Handling and Software in Abdominal Sonography</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39272698-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This is the first comprehensive study to directly compare different HHUS devices in a head-to-head manner. While the majority of the tested devices demonstrated satisfactory performance, notable discrepancies were observed between them. In particular, the B-scan quality exhibited considerable variation, which may have implications for the clinical application of HHUS. The findings of this study can assist in the selection of an appropriate HHUS device for specific &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39272752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Impact of Structured Reporting of Lower Extremity CT Angiography on Report Quality and Workflow Efficiency</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39272752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We assessed the effects of structured reporting (SR) of lower extremity CT angiography (CTA) on report quality and workflow efficiency compared with conventional reports (CR). Surveys were conducted at an academic radiology department before and after the introduction of an SR template. Participants (n = 39, 21) rated report quality and report creation effort (1: very dissatisfied/low to 10: very satisfied/high) and whether SR represents an improvement over CR (1: completely disagree to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39272856/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39272856-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39272868/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) â‰¤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39272868-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Percutaneous ablation is recommended in Barcelona Clinic Liver Cancer (BCLC) stage 0/A patients with HCC â‰¤3 cm as a curative treatment modality alongside surgical resection and liver transplantation. However, trans-arterial chemo-embolisation (TACE) is commonly used in the real-world as an initial treatment in patients with single small HCC in contrast to widely accepted clinical practice guidelines which typically describe TACE as a treatment for intermediate-stage HCC. We performed &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273014/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">PDCD10 Is a Key Player in TMZ-Resistance and Tumor Cell Regrowth: Insights into Its Underlying Mechanism in Glioblastoma Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273014-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Overcoming temozolomide (TMZ)-resistance is a major challenge in glioblastoma therapy. Therefore, identifying the key molecular player in chemo-resistance becomes urgent. We previously reported the downregulation of PDCD10 in primary glioblastoma patients and its tumor suppressor-like function in glioblastoma cells. Here, we demonstrate that the loss of PDCD10 causes a significant TMZ-resistance during treatment and promotes a rapid regrowth of tumor cells after treatment. PDCD10 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273106/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">BMP4-Induced Suppression of Breast Cancer Metastasis Is Associated with Inhibition of Cholesterol Biosynthesis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273106-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We reported previously that in preclinical models, BMP4 is a potent inhibitor of breast cancer metastasis and that high BMP4 protein levels predict favourable patient outcomes. Here, we analysed a breast cancer xenograft with or without enforced expression of BMP4 to gain insight into the mechanisms by which BMP4 suppresses metastasis. Transcriptomic analysis of cancer cells recovered from primary tumours and phosphoproteomic analyses of cancer cells exposed to recombinant BMP4 revealed &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273234/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Effects of Oxiris&lt;sup&gt;Â®&lt;/sup&gt; Therapy on Cytokine Elimination after a LPS Infusion-An Experimental Animal Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273234-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The clinical effectiveness of Oxiris^(Â®), particularly in reducing cytokines, remains uncertain due to the limited data provided. This study explored and analyzed the application value of Oxiris^(Â®) endotoxin adsorption technology in a large animal model. Pigs received an intravenous LPS infusion. Six animals were treated 2 h after the infusion with an Oxiris^(Â®) hemadsorption using a pumpless extracorporeal technique for 6 h. Five animals served as controls. Cardiocirculatory &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273340/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273340-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, with a high mortality rate due to the limited therapeutic options. Systemic drug treatments improve the patient&rsquo;s life expectancy by only a few months. Furthermore, the development of novel small molecule chemotherapeutics is time-consuming and costly. Drug repurposing has been a successful strategy for identifying and utilizing new therapeutic options for diseases with limited treatment options. This study aims &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273499/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273499-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Immune activation status determines non-small cell lung cancer (NSCLC) prognosis, with reported positive/negative associations for T helper type 2 (TH2) responses, including allergen-specific IgE and eosinophils. Our study seeks to explore the potential impact of these comorbid immune responses on the survival rates of patients with NSCLC. Our retrospective study used data from the Data Warehouse of the German Center for Lung Research (DZL) and Lung Biobank at Thoraxklinik Heidelberg. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273576/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">The Molecular and Immunological Landscape of Meningiomas</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273576-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Meningiomas are the most common primary intracranial tumors in adults and typically have a slow-growing and benign nature. However, there is also a substantial subset of meningiomas that shows aggressive clinical behavior and is refractory to standard treatment modalities, which are still limited to surgery and/or radiotherapy. Despite intensive research, no systemic treatment options are yet available in the clinic for these challenging tumors, resulting in poor patient outcome. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39273646/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Anti-Inflammatory and Anti-(Lymph)angiogenic Properties of an ABCB5&#43; Limbal Mesenchymal Stem Cell Population</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39273646-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Corneal transparency and avascularity are essential for vision. The avascular cornea transitions into the vascularized conjunctiva at the limbus. Here, we explore a limbal stromal cell sub-population that expresses ABCB5 and has mesenchymal stem cell characteristics. Human primary corneal stromal cells were enriched for ABCB5 by using FACS sorting. ABCB5+ cells expressed the MSC markers CD90, CD73, and CD105. ABCB5+ but not ABCB5- cells from the same donor displayed evidence of pluripotency &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39274320/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) Grade-Based Guidelines on the Surgical Treatment of Obesity Using Multimodal Strategies: Design and Methodological Aspects</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39274320-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: The prevalence of obesity is already a worldwide health concern. The development of straightforward guidelines regarding the whole available armamentarium (i.e., medical, endoscopic, and surgical interventions in conjunction with a guidance program) is paramount to offering the best multimodal approach to patients with obesity. Methods: The International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) identified a panel of experts to develop &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39274363/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Age-Related Outcomes in Heart Failure with Mildly Reduced Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39274363-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Objective: This study investigates age-related differences and outcomes in patients hospitalized with heart failure with a mildly reduced ejection fraction (HFmrEF). Background: The characterization of patients with HFmrEF and the prognostic value of age has rarely been investigated. Methods: Patients with HFmrEF were retrospectively included at one institution between 2016 and 2022. The distribution of HF aetiology and prognostic outcomes were investigated comparing patients with â‰¤40, &gt;40 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39274400/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Mid-Term Migration Pattern of a Cemented Collared Anatomical Stem-A Retrospective Study Using EBRA-FCA</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39274400-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: Aseptic loosening is one of the leading causes of stem revision. Einzel Bild RÃ¶ntgen Analyse-Femoral Component Analysis allows for the detection of distal stem migration, which is used as a predictive factor for implant longevity. This study aims to demonstrate the migration behavior of a cemented collared anatomical stem. Methods: This study retrospectively examined all patients who received a cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) between 2003 and 2019. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39274457/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Feasibility and Safety of 3D-Navigated Trans-Sacral Bar Osteosynthesis for Fragility Fractures of the Sacrum: FIRST Clinical Experiences</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39274457-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: There has been an increasing number of fragility fractures of the sacrum in the recent decade. With rates of up to 28%, the complication rates after surgical treatment are still at an unacceptably high level, and new treatment strategies are urgently needed. Therefore, the purpose of this study was to evaluate the potential of 3D-navigated trans-sacral bar osteosynthesis in the surgical treatment of fragility fractures of the sacrum. Methods: Retrospectively, from 2017 to 2023, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39274611/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Dimensional Accuracy of Novel Vinyl Polysiloxane Compared with Polyether Impression Materials: An In Vitro Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39274611-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Transferring the intraoral situation accurately to the dental laboratory is crucial for fabricating precise restorations. This study aimed to compare the dimensional accuracy of a new hydrophilic quadrofunctional vinyl polysiloxane (VPS) and polyether (PE), in combination with different impression techniques (mono-phase single step or dual-phase single step). The reference model simulated a partially edentulous mandible. Stainless-steel precision balls were welded to specific teeth and were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39275979/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Setting up an institutional OMERO environment for bioimage data: Perspectives from both facility staff and users</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39275979-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Modern bioimaging core facilities at research institutions are essential for managing and maintaining high-end instruments, providing training and support for researchers in experimental design, image acquisition and data analysis. An important task for these facilities is the professional management of complex multidimensional bioimaging data, which are often produced in large quantity and very different file formats. This article details the process that led to successfully implementing &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39276119/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Factors Influencing Long-term Outcomes After Matrix-Induced Autologous Chondrocyte Implantation: Long-term Results at 10 Years</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39276119-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The present study shows consistently good long-term clinical outcomes after MACI with a low revision rate and high patient satisfaction. BMI and number of previous knee surgeries may influence clinical outcomes and should be considered in patient selection and education. There is a correlation between graft structure, subchondral bone changes on magnetic resonance imaging, and long-term &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39276145/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">EuMAR stakeholder engagement: an analysis of medically assisted reproduction (MAR) data collection practices in EU countriesâ€ </a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39276145-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    STUDY QUESTION: What are the current national medically assisted reproduction (MAR) data collection systems across EU Member States, and how can these countries contribute to a unique, cycle-by-cycle registry for the European Monitoring of Medically Assisted Reproduction (EuMAR) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39276227/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240914193229&amp;v=2.18.0.post9&#43;e462414">Digital remote monitoring of chronic retinal conditions-A clinical future tool? : Remote monitoring of chronic retinal conditions</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39276227-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240914193229-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Remote monitoring could complement existing care structures for patients with chronic retinal diseases, especially AMD and DED. Promising systems are based on hyperacuity or optical coherence tomography, while patient-reported data are not commonly used; however, there is currently insufficient evidence justifying the use of remote monitoring systems in chronic retinal diseases in Europe and more research on the validation of remote monitoring systems is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OwUyY8KpD">ä»Šå¤©therapistè¯´â€off record, I enjoy talking to youâ€ã€‚æˆ‘ä»¬ç”¨äº†å¾ˆä¹…èŠäº†CBTå¾ªè¯ï¼Œç„¶åæˆ‘ç»™ä»–çœ‹äº†ä¸€ä¸‹æˆ‘ä»¬æ˜¨å¤©æ–°é—»å‘å¸ƒï¼Œè§£é‡Šäº†ä¸´åºŠè¯•éªŒæ„ä¹‰ã€‚æˆ‘è¯´æˆ‘ä»¬å·¥ä½œéƒ½...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-owuyy8kpd/">
    
    
    
    
    
      
    
    ä»Šå¤©therapistè¯´â€off record, I enjoy talking to youâ€ã€‚æˆ‘ä»¬ç”¨äº†å¾ˆä¹…èŠäº†CBTå¾ªè¯ï¼Œç„¶åæˆ‘ç»™ä»–çœ‹äº†ä¸€ä¸‹æˆ‘ä»¬æ˜¨å¤©æ–°é—»å‘å¸ƒï¼Œè§£é‡Šäº†ä¸´åºŠè¯•éªŒæ„ä¹‰ã€‚æˆ‘è¯´æˆ‘ä»¬å·¥ä½œéƒ½æ˜¯çœ‹chartã€‚æˆ‘è§‰å¾—æœ€è¿‘å‡ æ¬¡æˆ‘ä»¬æ›´åƒæ˜¯åŒäº‹è®¨è®ºé¡¹ç›®å’Œæ•°æ®ï¼Œè€Œä¸æ˜¯åœ¨åštherapyã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OwWkdjfbv">å‘¨äº”æ™šä¸Š11ç‚¹äº†åŒäº‹ä»¬è¿˜åœ¨æ ¸å¯¹æ•°æ®ã€‚æˆ‘ä»Šå¤©è·Ÿæˆ‘therapistè¯´åˆ°è¿™ç‚¹ï¼Œä»–è¯´è¿™å¯¹ä½ æ¥è¯´ä¸æ˜¯å·¥ä½œï¼Œè€Œæ˜¯passionã€‚å…¶å®åœ¨HIVé¢†åŸŸï¼Œè¿™ä¹ˆå¤šå¹´æˆ‘è®¤è¯†çš„åŒäº‹æœ‹å‹å¾ˆå¤šäººéƒ½æ˜¯...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-owwkdjfbv/">
    
    
    
    
    
      
    
    å‘¨äº”æ™šä¸Š11ç‚¹äº†åŒäº‹ä»¬è¿˜åœ¨æ ¸å¯¹æ•°æ®ã€‚æˆ‘ä»Šå¤©è·Ÿæˆ‘therapistè¯´åˆ°è¿™ç‚¹ï¼Œä»–è¯´è¿™å¯¹ä½ æ¥è¯´ä¸æ˜¯å·¥ä½œï¼Œè€Œæ˜¯passionã€‚å…¶å®åœ¨HIVé¢†åŸŸï¼Œè¿™ä¹ˆå¤šå¹´æˆ‘è®¤è¯†çš„åŒäº‹æœ‹å‹å¾ˆå¤šäººéƒ½æ˜¯å› ä¸ºçº¯ç²¹çš„passionè€Œç•™åœ¨è¿™ä¸ªé¢†åŸŸã€‚å°¤å…¶æ˜¯ç°åœ¨ï¼Œæˆ‘çœ‹åˆ°æ¯ä¸ªæ•°æ®ç‚¹ï¼Œéƒ½æ˜¯ä¸€ä¸ªæ´»ç”Ÿç”Ÿçš„äººï¼Œå¯¹ä»–ä»¬è€Œè¨€ï¼Œç»å†HIVæ„ŸæŸ“éƒ½æ˜¯äººç”Ÿæœ€å¤§å›°å¢ƒä¹‹ä¸€ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OwXmc0v5b">Barouchç»„åœ¨Nature Medå‘è¡¨äº†ä¸€é¡¹HIVä¸­å’ŒæŠ—ä½“ï¼ˆbNAbsï¼‰ç”¨äºHIVæ²»ç–—çš„ä¸´åºŠè¯•éªŒç»“æœï¼Œè¿™æ˜¯è¯¥ç ”ç©¶ç»„ä»æ’æ²³çŒ´æ¨¡å‹è½¬å‹ä¸´åºŠè¯•éªŒåç¬¬äºŒç¯‡ä¸­å’ŒæŠ—ä½“ä¸´åºŠè¯•éªŒç ”ç©¶è®ºæ–‡ï¼Œä¹‹...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-owxmc0v5b/">
    
    
    
    
    
      
    
    Barouchç»„åœ¨Nature Medå‘è¡¨äº†ä¸€é¡¹HIVä¸­å’ŒæŠ—ä½“ï¼ˆbNAbsï¼‰ç”¨äºHIVæ²»ç–—çš„ä¸´åºŠè¯•éªŒç»“æœï¼Œè¿™æ˜¯è¯¥ç ”ç©¶ç»„ä»æ’æ²³çŒ´æ¨¡å‹è½¬å‹ä¸´åºŠè¯•éªŒåç¬¬äºŒç¯‡ä¸­å’ŒæŠ—ä½“ä¸´åºŠè¯•éªŒç ”ç©¶è®ºæ–‡ï¼Œä¹‹å‰çš„ç ”ç©¶ç»“æœåŒæ ·å‘è¡¨åœ¨äº†Nature Medä¸Šï¼ˆ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç½‘é¡µé“¾æ¥<!-- raw HTML omitted --><!-- raw HTML omitted -->ï¼‰ï¼›è¿™ä¹Ÿæ˜¯ä¹‹å‰ç ”ç©¶çš„åç»­ç ”ç©¶ï¼Œä¸ºHIV-1  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/OwUKJ34Yd">æ•¦ç…Œåšç‰©é¦†é—¨å£ï¼Œæœ‰ä¸€å®¶åŠ¨ç‰©åŒ»é™¢ã€‚ä¸€çœ‹å°±æ˜¯ä¸“ä¸ºç‰›ã€é©¬ã€é©¬å–½è¿™æ ·çš„åŠ¨ç‰©çœ‹ç—…çš„ï¼Œç™½é¢†åŠ¨ç‰©å¦‚ç‹—ã€é¹¦é¹‰ã€èœ¥èœ´ä¹‹ç±»ï¼Œå¤§æ¦‚æœ‰æ›´é«˜çº§çš„å¯¹å£åŒ»é™¢ã€‚è‡³äºé‡‘é¢†çŒ«ï¼Œææ€•æ˜¯ä¸“å±...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-owukj34yd/">
    
    
    
    
    
      
    
    æ•¦ç…Œåšç‰©é¦†é—¨å£ï¼Œæœ‰ä¸€å®¶åŠ¨ç‰©åŒ»é™¢ã€‚ä¸€çœ‹å°±æ˜¯ä¸“ä¸ºç‰›ã€é©¬ã€é©¬å–½è¿™æ ·çš„åŠ¨ç‰©çœ‹ç—…çš„ï¼Œç™½é¢†åŠ¨ç‰©å¦‚ç‹—ã€é¹¦é¹‰ã€èœ¥èœ´ä¹‹ç±»ï¼Œå¤§æ¦‚æœ‰æ›´é«˜çº§çš„å¯¹å£åŒ»é™¢ã€‚è‡³äºé‡‘é¢†çŒ«ï¼Œææ€•æ˜¯ä¸“å±å®¶åº­åŒ»ç”Ÿäº†å§ï¼Ÿ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/OwVSUqKBx">è·¯é‡ä¸€å®¶å­Ÿå©†ç²‰â€¦â€¦åº—ä¸»å¥½åƒå¿˜äº†å¼€åº—äº† æŸ¥çœ‹å›¾ç‰‡ - è½¬å‘ @é©¬ä¼¯åº¸:&amp;ensp;æ•¦ç…Œåšç‰©é¦†é—¨å£ï¼Œæœ‰ä¸€å®¶åŠ¨ç‰©åŒ»é™¢ã€‚ä¸€çœ‹å°±æ˜¯ä¸“ä¸ºç‰›ã€é©¬ã€é©¬å–½è¿™æ ·çš„åŠ¨ç‰©çœ‹ç—…çš„ï¼Œç™½é¢†åŠ¨ç‰©...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-owvsuqkbx/">
    
    
    
    
    
      
    
    è·¯é‡ä¸€å®¶å­Ÿå©†ç²‰â€¦â€¦åº—ä¸»å¥½åƒå¿˜äº†å¼€åº—äº† <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¥çœ‹å›¾ç‰‡<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é©¬ä¼¯åº¸<!-- raw HTML omitted -->:â€‚æ•¦ç…Œåšç‰©é¦†é—¨å£ï¼Œæœ‰ä¸€å®¶åŠ¨ç‰©åŒ»é™¢ã€‚ä¸€çœ‹å°±æ˜¯ä¸“ä¸ºç‰›ã€é©¬ã€é©¬å–½è¿™æ ·çš„åŠ¨ç‰©çœ‹ç—…çš„ï¼Œç™½é¢†åŠ¨ç‰©å¦‚ç‹—ã€é¹¦é¹‰ã€èœ¥èœ´ä¹‹ç±»ï¼Œå¤§æ¦‚æœ‰æ›´é«˜çº§çš„å¯¹å£åŒ»é™¢ã€‚è‡³äºé‡‘é¢†çŒ« &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0dDthdx">ğŸ”»çœ‹äº†ç¬¬å››å±€ï¼Œå¹´è½»äººæ‰“çš„æŒºå¥½çš„ã€‚#ç‹æ¥šé’¦vsæ—è¯—æ ‹#</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0ddthdx/">
    
    
    
    
    
      
    
    ğŸ”»çœ‹äº†ç¬¬å››å±€ï¼Œå¹´è½»äººæ‰“çš„æŒºå¥½çš„ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ç‹æ¥šé’¦vsæ—è¯—æ ‹#<!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0eD7ad6">ä½†æ˜¯æœ‰äº›æœ‰è´£ä»»æ ¸å®ä¿¡æ¯çš„æœ‰å½±å“åŠ›å¸å·ä¹Ÿè·Ÿç€åœ¨è¿™å„¿æ¬¢å‘¼â€œå¤–å›½äººæ•´é¡¿ç›¸äº²å¸‚åœºâ€äº†ï¼Œå°±æ²¡æ„æ€äº†ï¼Œéª—éª—è‡ªå·±å°±è¡Œäº†å‘—ï¼Œè¿˜çœŸéª—å“¥ä»¬å„¿å•Šï¼Ÿ//@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:å…¶å®ä¹Ÿæ²¡...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0ed7ad6/">
    
    
    
    
    
      
    
    ä½†æ˜¯æœ‰äº›æœ‰è´£ä»»æ ¸å®ä¿¡æ¯çš„æœ‰å½±å“åŠ›å¸å·ä¹Ÿè·Ÿç€åœ¨è¿™å„¿æ¬¢å‘¼â€œå¤–å›½äººæ•´é¡¿ç›¸äº²å¸‚åœºâ€äº†ï¼Œå°±æ²¡æ„æ€äº†ï¼Œéª—éª—è‡ªå·±å°±è¡Œäº†å‘—ï¼Œè¿˜çœŸéª—å“¥ä»¬å„¿å•Šï¼Ÿ//<!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:å…¶å®ä¹Ÿæ²¡å•¥ï¼Œä¸€ç§åˆ›ä½œæ€è·¯å˜›ã€‚é™¤äº†å¢åŠ æœ‰äº›å“¥ä»¬å„¿çš„ç„¦è™‘ä»¥å¤–ä¹Ÿæ²¡æœ‰ä»€ä¹ˆåˆ«çš„åå¤„ã€‚æ¯•ç«Ÿä¸æ˜¯ä¸€ä¸ªèµ›é“çš„ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»è§†é¢‘1å¸å· Cå¦¹åœ¨æˆéƒ½ï¼ŒæŠ–éŸ³118.3ä¸‡ç²‰ã€‚<!-- raw HTML omitted -->ğŸ”»è§†é¢‘2å¸å· JCåœ¨æˆéƒ½ï¼ŒæŠ–éŸ³111.9ä¸‡ç²‰ã€‚<!-- raw HTML omitted -->ğŸ”»è§†é¢‘3å¸å· é˜¿çåœ¨åŒ—äº¬ï¼ŒæŠ–éŸ³133.7ä¸‡ç²‰ã€‚<!-- raw HTML omitted -->ğŸ”»è§†é¢‘4å¸å· LUNAåœ¨å¹¿å·ï¼ŒæŠ–éŸ³159.9ä¸‡ç²‰ã€‚<!-- raw HTML omitted -->ğŸ”»è¿™äº›å¸å·å•†åŠ¡åˆä½œå¸å·è”ç³»äººä¸€æ ·ï¼Œæœ‰ä¸šåŠ¡éœ€æ±‚çš„ï¼Œè”ç³»ä¸€ä¸ªå°±è¡Œäº†ï¼Œçœäº‹çœå¿ƒã€‚ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/639b">https://tvax3.sinaimg.cn/large/639b</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0g2hiTF">ğŸ”»å°åº¦çš„å…¬è·¯å¡Œæ–¹éƒ½å¾ˆæœ‰è¾¨æåº¦ã€‚ğŸ”»via ç«å±±è¿·ç¾å®³èµ„è®¯ç½‘#çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0g2hitf/">
    
    
    
    
    
      
    
    ğŸ”»å°åº¦çš„å…¬è·¯å¡Œæ–¹éƒ½å¾ˆæœ‰è¾¨æåº¦ã€‚<!-- raw HTML omitted -->ğŸ”»via ç«å±±è¿·ç¾å®³èµ„è®¯ç½‘<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div style=&ldquo;clear: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0Q8rghy">ä½ æ€ä¹ˆçŸ¥é“æˆ‘ä¹°äº†åŸä»·çš„å“ˆç«‹å¾·1ç¤¼åŒ…ï¼Ÿ//@è®¸è¯ºä¸æƒ³è¯´è¯:åŒ…å§åˆ«æ€¥ï¼Œæ—©æ™šä¼šæœ‰å±äºä½ çš„æ‹‰å¤«é©¾ç€å·¨å¤§å¤©ç‡•90æ¥è¿å¨¶ä½ [doge] - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»äº’è”ç½‘...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0q8rghy/">
    
    
    
    
    
      
    
    ä½ æ€ä¹ˆçŸ¥é“æˆ‘ä¹°äº†åŸä»·çš„å“ˆç«‹å¾·1ç¤¼åŒ…ï¼Ÿ//<!-- raw HTML omitted -->@è®¸è¯ºä¸æƒ³è¯´è¯<!-- raw HTML omitted -->:åŒ…å§åˆ«æ€¥ï¼Œæ—©æ™šä¼šæœ‰å±äºä½ çš„æ‹‰å¤«é©¾ç€å·¨å¤§å¤©ç‡•90æ¥è¿å¨¶ä½ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»äº’è”ç½‘ä¸Šæ¯ä¸ªç¾¤ä½“ï¼Œéƒ½èƒ½åŒ¹é…åˆ°é€‚åˆè‡ªå·±çš„ä¼æ‹‰å¤«ã€‚ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0rMf5SR">ä¼Šæˆˆå°”Â·ç»´å…‹æ‰˜ç½—ç»´å¥‡Â·æ™®æµå…‹åœ¨é¡¿æ¶…èŒ¨å…‹åæ°”æŒºå¤§ï¼Œç°åœ¨æ˜¯ä¸Šæ ¡ï¼Œè¯è¯´ DNR å†…éƒ¨ä¸‘é—»ä¹Ÿä¸å°‘ï¼Œä»”ç»†æƒ³æƒ³é‚£ä¹ˆå¤šæˆ˜æ–—è‹±é›„é™†é™†ç»­ç»­æ˜¯æ€ä¹ˆè¢«æš—æ€çš„ã€‚å¾ˆå¤šäººå› ä¸ºè¿™ä»¶äº‹æ›...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0rmf5sr/">
    
    
    
    
    
      
    
    ä¼Šæˆˆå°”Â·ç»´å…‹æ‰˜ç½—ç»´å¥‡Â·æ™®æµå…‹åœ¨é¡¿æ¶…èŒ¨å…‹åæ°”æŒºå¤§ï¼Œç°åœ¨æ˜¯ä¸Šæ ¡ï¼Œè¯è¯´ DNR å†…éƒ¨ä¸‘é—»ä¹Ÿä¸å°‘ï¼Œä»”ç»†æƒ³æƒ³é‚£ä¹ˆå¤šæˆ˜æ–—è‹±é›„é™†é™†ç»­ç»­æ˜¯æ€ä¹ˆè¢«æš—æ€çš„ã€‚å¾ˆå¤šäººå› ä¸ºè¿™ä»¶äº‹æ›å…‰ï¼ŒåˆæŠŠæ‹‰å¡å°”Â·æœ¬ç‰¹åˆ©æ¡ˆè”ç³»åœ¨äº†ä¸€èµ·ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å‘¦å¼å•Šå‘¦å¼å‘¦å¼<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¿„ä¹Œå±€åŠ¿#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%BF%84%E4%B9%8C%E5%B1%80%E5%8A%BF%E6%96%B0%E8%BF%9B%E5%B1%95%23&amp;amp;extparam=%23%E4%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%BF%84%E4%B9%8C%E5%B1%80%E5%8A%BF%E6%96%B0%E8%BF%9B%E5%B1%95%23&amp;amp;extparam=%23%E4%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0vNjVFP">ğŸ”»äº’è”ç½‘ä¸Šæ¯ä¸ªç¾¤ä½“ï¼Œéƒ½èƒ½åŒ¹é…åˆ°é€‚åˆè‡ªå·±çš„ä¼æ‹‰å¤«ã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0vnjvfp/">
    
    
    
    
    
      
    
    ğŸ”»äº’è”ç½‘ä¸Šæ¯ä¸ªç¾¤ä½“ï¼Œéƒ½èƒ½åŒ¹é…åˆ°é€‚åˆè‡ªå·±çš„ä¼æ‹‰å¤«ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox0yXwfiP">ğŸ”»è°¢è°¢å®ˆå¤œäººï¼Œæ™šå®‰ã€‚ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox0yxwfip/">
    
    
    
    
    
      
    
    ğŸ”»è°¢è°¢å®ˆå¤œäººï¼Œæ™šå®‰ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox14PCnBL">ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼šğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½ä»¤ï¼šä¿„è”é‚¦å›½é˜²éƒ¨å‰¯éƒ¨é•¿å…¼ä¿„è”é‚¦æ­¦è£…åŠ›é‡å†›äº‹æ”¿æ²»æ€»å±€å±€é•¿ç»´å…‹æ‰˜-æˆˆåˆ—ç±³é‡‘ä¸Šå°†ã€ä¿„ç½—æ–¯è”é‚¦æ­¦è£…åŠ›é‡æ€»...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox14pcnbl/">
    
    
    
    
    
      
    
    ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼š<!-- raw HTML omitted -->ğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½ä»¤ï¼šä¿„è”é‚¦å›½é˜²éƒ¨å‰¯éƒ¨é•¿å…¼ä¿„è”é‚¦æ­¦è£…åŠ›é‡å†›äº‹æ”¿æ²»æ€»å±€å±€é•¿ç»´å…‹æ‰˜-æˆˆåˆ—ç±³é‡‘ä¸Šå°†ã€ä¿„ç½—æ–¯è”é‚¦æ­¦è£…åŠ›é‡æ€»å‚è°‹é•¿å…¼ä¿„ç½—æ–¯è”é‚¦å›½é˜²éƒ¨ç¬¬ä¸€å‰¯éƒ¨é•¿ç“¦åˆ—é‡Œ-æ ¼æ‹‰è¥¿è«å¤«é™†å†›ä¸Šå°†ï¼Œç«‹å³ä¸ä¿„ç½—æ–¯è”é‚¦å®‰å…¨å±€å†›äº‹åæƒ…æŠ¥å¸ä¸€é“ï¼Œå°½å¿«å¤„ç†ä¸ä¸¤åå‘¼å·ä¸ºâ€˜æ¬§å†…æ–¯ç‰¹â€™å’Œâ€˜åº·æ–¯å¦ä¸â€™çš„å†›äººæ­» äº¡ æœ‰ å…³ çš„ æ¡ˆä»¶ã€‚â€<!-- raw HTML omitted -->ğŸ”»ä¼—æ‰€å‘¨çŸ¥ï¼Œåˆ«æ´›ç´¢å¤«é¢†å—ç€æ™®äº¬çš„ä»»åŠ¡ï¼Œæ­£åœ¨ä¿„ç½—æ–¯å›½é˜²éƒ¨å†…å¤§åˆ€é˜”æ–§æ¸…ç†é—¨æˆ·ã€‚<!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/639b1bfbly1htnsjne50rj20p017n7pd.jpg%22">https://tvax1.sinaimg.cn/large/639b1bfbly1htnsjne50rj20p017n7pd.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox1ehtrGz">æ‰“é›·å‘¢ï¼Œæ²¡åŠæ³•ï¼Œæ‰“æˆ˜é›·å§ã€‚//@bbq77882011:åŒ…å§ï¼Œ2ç‚¹å¤šäº†ï¼Œè¿˜æ²¡ç¡å•Šï¼Ÿ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼šğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox1ehtrgz/">
    
    
    
    
    
      
    
    æ‰“é›·å‘¢ï¼Œæ²¡åŠæ³•ï¼Œæ‰“æˆ˜é›·å§ã€‚//<!-- raw HTML omitted -->@bbq77882011<!-- raw HTML omitted -->:åŒ…å§ï¼Œ2ç‚¹å¤šäº†ï¼Œè¿˜æ²¡ç¡å•Šï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼š<!-- raw HTML omitted -->ğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½ä»¤ï¼šä¿„è”é‚¦å›½é˜²éƒ¨å‰¯éƒ¨é•¿å…¼ä¿„è”é‚¦æ­¦è£…åŠ›é‡å†›äº‹æ”¿æ²»æ€»å±€å±€é•¿ç»´å…‹æ‰˜-æˆˆåˆ—ç±³é‡‘ä¸Šå°†ã€ä¿„ç½—æ–¯è”é‚¦æ­¦è£…åŠ›é‡æ€»å‚è°‹é•¿å…¼ä¿„ç½—æ–¯è”é‚¦å›½é˜²éƒ¨ç¬¬ä¸€å‰¯éƒ¨é•¿ç“¦åˆ—é‡Œ-æ ¼æ‹‰è¥¿è«å¤«é™†å†›ä¸Šå°†ï¼Œç«‹å³ä¸ä¿„ç½—æ–¯è”é‚¦å®‰å…¨å±€å†›äº‹åæƒ…æŠ¥å¸ä¸€é“ï¼Œå°½å¿«å¤„ç†ä¸ä¸¤åå‘¼å·ä¸ºâ€˜æ¬§å†…æ–¯ç‰¹â€™å’Œâ€˜åº·æ–¯å¦ä¸â€™çš„å†›äººæ­» äº¡ æœ‰ å…³ çš„ æ¡ˆä»¶ã€‚â€<!-- raw HTML omitted -->ğŸ”»ä¼—æ‰€å‘¨çŸ¥ï¼Œåˆ«æ´›ç´¢å¤«é¢†å—ç€æ™®äº¬çš„ä»»åŠ¡ï¼Œæ­£åœ¨ä¿„ç½—æ–¯å›½é˜²éƒ¨å†…å¤§åˆ€é˜”æ–§æ¸…ç†é—¨æˆ·ã€‚&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/639b1bf">https://tvax3.sinaimg.cn/large/639b1bf</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ox1xZBA9U">æ–°å®˜ä¸Šä»»ä¸‰æŠŠç« - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼šğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½ä»¤ï¼šä¿„è”é‚¦å›½é˜²éƒ¨å‰¯éƒ¨é•¿å…¼ä¿„è”é‚¦æ­¦è£…åŠ›é‡å†›äº‹æ”¿æ²»æ€»å±€å±€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ox1xzba9u/">
    
    
    
    
    
      
    
    æ–°å®˜ä¸Šä»»ä¸‰æŠŠç«<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»ä¿„ç½—æ–¯å›½é˜²éƒ¨å®˜ç½‘ï¼š<!-- raw HTML omitted -->ğŸ”»â€œä¿„è”é‚¦å›½é˜²éƒ¨é•¿åˆ«æ´›ç´¢å¤«å·²å‘½ä»¤ï¼šä¿„è”é‚¦å›½é˜²éƒ¨å‰¯éƒ¨é•¿å…¼ä¿„è”é‚¦æ­¦è£…åŠ›é‡å†›äº‹æ”¿æ²»æ€»å±€å±€é•¿ç»´å…‹æ‰˜-æˆˆåˆ—ç±³é‡‘ä¸Šå°†ã€ä¿„ç½—æ–¯è”é‚¦æ­¦è£…åŠ›é‡æ€»å‚è°‹é•¿å…¼ä¿„ç½—æ–¯è”é‚¦å›½é˜²éƒ¨ç¬¬ä¸€å‰¯éƒ¨é•¿ç“¦åˆ—é‡Œ-æ ¼æ‹‰è¥¿è«å¤«é™†å†›ä¸Šå°†ï¼Œç«‹å³ä¸ä¿„ç½—æ–¯è”é‚¦å®‰å…¨å±€å†›äº‹åæƒ…æŠ¥å¸ä¸€é“ï¼Œå°½å¿«å¤„ç†ä¸ä¸¤åå‘¼å·ä¸ºâ€˜æ¬§å†…æ–¯ç‰¹â€™å’Œâ€˜åº·æ–¯å¦ä¸â€™çš„å†›äººæ­» äº¡ æœ‰ å…³ çš„ æ¡ˆä»¶ã€‚â€<!-- raw HTML omitted -->ğŸ”»ä¼—æ‰€å‘¨çŸ¥ï¼Œåˆ«æ´›ç´¢å¤«é¢†å—ç€æ™®äº¬çš„ä»»åŠ¡ï¼Œæ­£åœ¨ä¿„ç½—æ–¯å›½é˜²éƒ¨å†…å¤§åˆ€é˜”æ–§æ¸…ç†é—¨æˆ·ã€‚<!-- raw HTML omitted -->&lt;img style=&quot;&quot;  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OwWkQ6m1n">ä¹…ä¿ç”¨å¤§å§æ‰‹æ©Ÿæ‹çš„è‡ªæ‹ç…§ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-owwkq6m1n/">
    
    
    
    
    
      
    
    ä¹…ä¿ç”¨å¤§å§æ‰‹æ©Ÿæ‹çš„è‡ªæ‹ç…§ <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OwYwZETGY">æ€éº¼é€™éº¼å¥½çœ‹å•Šï¼ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-owywzetgy/">
    
    
    
    
    
      
    
    æ€éº¼é€™éº¼å¥½çœ‹å•Šï¼ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OwXsPnauM">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.09.14 13:57ã€Œæ—¶é’Ÿã€æ—©ä¸Šå¥½ä»Šå¤©ä¹ŸåŠªåŠ›å§ä»Šæ—©æ—¶éš”è®¸ä¹…åœ°èµ·æ¥å¾—å¾ˆå¹²è„†å‘¢è™½ç„¶ä¹Ÿä¼šæœ‰å®³æ€•èµ·åºŠçš„æ—¥å­å’Œå¾ˆéš¾èµ·åºŠçš„æ—¥å­ä½†æ˜¯è¦åŠªåŠ›...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-owxspnaum/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%258">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OwXtEdO8q">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¢«æ‰¾åˆ°äº†ğŸ«£ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-owxtedo8q/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->è¢«æ‰¾åˆ°äº†ğŸ«£ &lt;img &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OwYls0ist">ä¹…ä¿å²ç»ªé‡Œ[æŠ±ä¸€æŠ±] - è½¬å‘ @é•·äº­æ¢…:&amp;ensp;æ¢…æ³½ç¾æ³¢#æ¢…æ³½ç¾æ³¢# å¤ã®ãƒ„ã‚¢ãƒ¼ã€å®Œèµ°ã—ã¾ã—ãŸä¹ƒæœ¨å‚ã§éã”ã™å¤ã¯ã„ã¤ã‚‚ã€å˜ç´”ã«ã¯çµ‚ã‚ã‚Œã¾ã›ã‚“ã€‚æ„Ÿæƒ…ãŒ å‡„ã¾ã˜ãå‹•ã...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-owyls0ist/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img alt=&quot;[æŠ±ä¸€æŠ±]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/default/co_a1hug-f3910d0e88.png%22">https://h5.sinaimg.cn/m/emoticon/icon/default/co_a1hug-f3910d0e88.png&quot;</a> style=&ldquo;width:1em; height:1em;&rdquo; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OwYqycZrD">ä¹…ä¿å²ç»ªé‡Œ[äº²äº²] - è½¬å‘ @ç‰¹è•¾çº±ç†ŠçŒ«è¦³å¯Ÿä¼š:&amp;ensp;æ± ç”°ç‘›çº±#terepantalk# 5566ï½œ2024-09-14 20:04:26ï½œå›¾ç‰‡ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-owyqyczrd/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OwYrvzm52">ä¹…ä¿å²ç»ªé‡Œ[å“‡] - è½¬å‘ @ç‰¹è•¾çº±ç†ŠçŒ«è¦³å¯Ÿä¼š:&amp;ensp;æ± ç”°ç‘›çº±#terepantalk# 5567ï½œ2024-09-14 20:04:45ï½œå›¾ç‰‡ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-14</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-owyrvzm52/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;blockquo &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

